Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 963 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Airway Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Oral Cyclosporine in Chronic Obstructive Pulmonary Disease

NCT00974142
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Cyclosporine, Placebo
Drug
Lead sponsor
Michael Donahoe
Other
Eligibility
45 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)

NCT01426581
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Teach-To-Goal, Brief Intervention
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

IVR-Enhanced Care Transition Support for Complex Patients

NCT01135381
View directory record Official record
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
IVR-Enhanced Care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

De-implementing Inhaled Steroids to Improve Care and Safety in COPD

NCT02896257
View directory record Official record
Conditions
Treatment of Chronic Obstructive Pulmonary Disease
Interventions
Guideline treatment recommendations
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Bedford, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 11, 2026, 8:53 PM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

NCT01336608
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate/Vilanterol, Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging Lung Function Using Oxygen Enhanced MRI

NCT01731015
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Disease
Interventions
Medical Grade Oxygen
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease

NCT01372462
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NIOV - Room Air, NIOV - Oxygen, Nasal Cannula Oxygen
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

NCT02662582
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Reldesemtiv, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Torrance, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 1Phase 2 Interventional

Dyspnea Self-Management: Internet or Face-to-Face

NCT00461162
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Internet DSMP, Face-to-Face Dyspnea Self-management, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 3 Interventional

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)

NCT00076089
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Roflumilast
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Cities in Alabama, Alabama • Cities in Arizona, Arizona • Cities in Arkansas, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 11, 2026, 8:53 PM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

12 / 48 wk Pivotal PFT vs PBO in COPD II

NCT00782509
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI 1744), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
28
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional

The Effect of OMT on Patients With COPD: Correlating Pulmonary Function Tests With Biochemical Alterations

NCT01582958
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Osteopathic Manipulative Treatment (OMT), sham omt
Procedure · Other
Lead sponsor
Michigan State University
Other
Eligibility
49 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 11, 2026, 8:53 PM EDT
Completed No phase listed Observational

Connect Lung Outcomes With Bronchodilator Use

NCT04417842
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Respimetrix flow-volume monitoring device
Diagnostic Test
Lead sponsor
Pulmonary Critical Care Associates of Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 11, 2026, 8:53 PM EDT
Completed No phase listed Observational

A Registry of COPD Patients to be Used for Future Studies

NCT00814203
View directory record Official record
Conditions
Chronic Obstructive Lung Disease
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04535986
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Peoria, Arizona • Tempe, Arizona • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional

A Trial to Reduce Readmissions Using Motivational Interviewing and Interactive Voice Response

NCT01855022
View directory record Official record
Conditions
Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
MI + IVR
Behavioral
Lead sponsor
Asante Health System
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Grants Pass, Oregon • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)

NCT01734473
View directory record Official record
Conditions
COPD
Interventions
Hydrolyzed casein protein, Hydrolyzed casein protein + carbohydrates, Hydrolyzed casein protein + leucine, Hydrolyzed casein protein + carbohydrates + leucine, 4 levels of hydrolyzed casein protein + carbohydrates
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 11, 2026, 8:53 PM EDT
Recruiting Phase 2 Interventional

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

NCT07037836
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia
Interventions
Inhaled Treprostinil (Tyvaso Nebulizer)
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 11, 2026, 8:53 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT04647383
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Interventions
Placebo, Lemborexant 10 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
11
States / cities
Glendale, Arizona • San Diego, California • Brandon, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 11, 2026, 8:53 PM EDT